Assessment of a self-administration protocol for extended subcutaneous thromboprophylaxis in lower limb arthroplasty

Journal of Bone and Joint Surgery - Series B

Volumn 88, Issue 1, 2006, Pages 107-110

  Watts, A C ^a   Howie, Colin R ^a   Simpson, A H R W ^a  

^a ROYAL INFIRMARY OF EDINBURGH   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

FIBRINOLYTIC AGENT; FONDAPARINUX; HISTAMINE H2 RECEPTOR ANTAGONIST;

ARTHROPLASTY; ARTICLE; BLOOD TRANSFUSION; CLINICAL ARTICLE; CLINICAL PROTOCOL; CLINICAL TRIAL; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; HEMATEMESIS; HIP ARTHROPLASTY; HUMAN; KNEE ARTHROPLASTY; MALE; PATIENT COMPLIANCE; PERIPHERAL EDEMA; POSTOPERATIVE CARE; POSTOPERATIVE THROMBOSIS; PRIORITY JOURNAL; RISK REDUCTION; SELF MEDICATION; SELF REPORT; TREATMENT OUTCOME;

ANTICOAGULANTS; ARTHROPLASTY, REPLACEMENT, HIP; ARTHROPLASTY, REPLACEMENT, KNEE; FEASIBILITY STUDIES; FEMALE; HAND; HUMANS; INJECTIONS, SUBCUTANEOUS; MALE; PATIENT COMPLIANCE; POLYSACCHARIDES; POSTOPERATIVE CARE; POSTOPERATIVE COMPLICATIONS; PROSPECTIVE STUDIES; SELF ADMINISTRATION; THROMBOEMBOLISM; VENOUS THROMBOSIS;

EID: 31144448014     PISSN: 0301620X     EISSN: None     Source Type: Journal    
DOI: 10.1302/0301-620X.88B1.17003     Document Type: Article

References (23)

1. Fender D, Harper WM, Thompson JR, Gregg PJ. Mortality and fatal pulmonary embolism after primary total hip replacement: results from a national hip register. J Bone Joint Surg [Br] 1997;79-B:896-9.
2. White RH, Zhou H, Romano PS. Incidence of symptomatic venous thromboembolism after different elective or urgent surgical procedures. Thromb Haemost 2003;90: 446-55.
3. Howie CR, Hughes H, Watts AC, Scottish Arthroplasty Project. Venous thrombosis and pulmonary embolism associated with hip and knee joint replacement over a ten-year period: a population-based study. J Bone Joint Surg [Br] 2005;87-B: 1675-80.
4. Brenkel IJ, Clancy MJ. Total hip replacement and antithrombotic prophylaxis. Br J Hosp Med 1989;42:282-4.
5. Francis RM, Brenkel IJ. Survey of use of thromboprophylaxis for routine total hip replacement by British orthopaedic surgeons. Br J Hosp Med 1997;57:427-31.
6. White RH, Romano PS, Zhou H, Rodrigo J, Bargar W. Incidence and time course of thromboembolic outcomes following total hip or knee arthroplasty. Arch Intern Med 1998;158:1525-31.
7. Planes A, Vochelle N, Darmon J-Y, et al. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: double-blind randomised comparison of enoxaparin versus placebo. Lancet 1996;348:224-8.
8. Bergqvist D, Benoni G, Bjorgell O, et al. Low-molecular-weight heparin (Enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement. N Engl J Med 1996;335:696-700.
9. Dahl OE, Andreassen G, Aspelin T, et al. Prolonged thromboprophylaxis following hip replacement surgery: results of a double-blind, prospective, randomised, placebo-controlled study with dalteparin (Gragmin). Thromb Haemost 1997;77:26-31.
10. Lassen MR, Borris LC, Anderson BS, et al. Efficacy and safety of prolonged thromboprophylaxis with a low molecular weight heparin (dalteparin) after total hip arthroplasty: the Danish Prolonged Prophylaxis (DaPP) study. Thromb Res 1998;89: 281-7.
11. Hull R, Pineo G, Francis C, et al. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: a double blind, randomized comparison. Arch Intern Med 2000;160:2208-15.
12. Comp PC, Spiro TE, Freidman RJ. Prolonged enoxaparin therapy to prevent venous thromoboembolism after primary hip or knee replacement. J Bone Joint Surg [Am] 2001;83-A:336-45.
13. Prandoni P, Bruchi O, Sabbion P, et al. Prolonged thromboprophylaxis with oral anticoagulants after total hip arthroplasty. Arch Intern Med 2002;162:1966-71.
14. Geerts WH, Pineo GF, Heit JA, et al. Prevention of venous thromboembolism. Chest 2004;126:338-400.
15. Beaton DE, Katz JN, Fossel AH, et al. Measuring the whole or the part?: validity, reliability, and responsiveness of the Disabilities of the Arm Shoulder and Hand outcome measure in different regions of the upper extremity. J Hand Ther 2001;14: 128-46.
16. Galster H, Kolb G, Kohsytorz A, Seidlmayer C, Paal V. The pre-, peri-, and post-surgical activation of coagulation and the thromboembolic risk for different risk groups. Thromb Res 2000;100:381-8.
17. Cohen AT, Bailey CS, Alikan R, Cooper DJ. Extended thromboprophylaxis with low molecular weight heparin reduces symptomatic venous thromboembolism following lower limb arthroplasty: a meta-analysis. Thromb Haemost 2001;85:940-1.
18. Kearon C. Duration of venous thromboembolism prophylaxis after surgery. Chest 2003;124:386-92.
19. Bauer KA, Eriksson BI, Lassen MR, Turpie AGG. Fondaparinux compared with enoxaparin for the prevention of venous thromboembolism after elective major knee surgery. N Engl J Med 2001;345:1305-10.
20. Nurmohamed MT, MacGillavry MR. Long-term thromboprophylaxis in practice: how can it be implemented? Orthopaedics 2000;23:47-50.
21. Eriksson BI, Lassen MR. Duration of prophylaxis against venous thromboembolism with fondaparinux after hip fracture surgery: a multicentre, randomized, placebo-controlled double-blind study. Arch Intern Med 2003;163:1337-42.
22. Sarasin FP, Bounameaux H. Out of hospital antithrombotic prophylaxis after total hip replacement: low-molecular-weight heparin, warfarin, aspirin or nothing? Thromb Haemost 2002;87:586-92.
23. Gordois A, Posnett J, Borris L, et al. The cost-effectiveness of fondaparinux compared with enoxaparin as prophylaxis against thromboembolism following major orthopaedic surgery. J Thromb Haemost 2003;1:2167-74.